Table 1 Baseline characteristics according to the treatment protocol group
From: Effects of a new nutraceutical combination on cognitive function in hypertensive patients
|  | Placebo (n = 18) | Active treatment (n = 18) | p |
|---|---|---|---|
Age (yrs) | 57.9 ± 6.7 | 58.2 ± 8.0 | 0.910 |
Males | 14 (77.8) | 13 (72.2) | 0.700 |
Height (cm) | 170.0 ± 9.2 | 170.2 ± 8.6 | 0.955 |
Weight (kg) | 75.9 ± 11.0 | 80.2 ± 15.7 | 0.351 |
Body Mass Index (kg/m2) | 26.3 ± 3.1 | 27.7 ± 2.8 | 0.161 |
SBP (mmHg) | 133.3 ± 16.9 | 135.6 ± 13.5 | 0.666 |
DBP (mmHg) | 84.1 ± 12.3 | 85.8 ± 9.1 | 0.636 |
Heart rate (bpm) | 68.8 ± 6.8 | 66.4 ± 7.9 | 0.350 |
Total cholesterol (mg/dl) | 198.2 ± 23.7 | 201.9 ± 27.5 | 0.667 |
HDL cholesterol (mg/dl) | 47.6 ± 7.9 | 51.3 ± 7.2 | 0.144 |
LDL cholesterol (mg/dl) | 129.2 ± 26.1 | 126.7 ± 30.4 | 0.789 |
Triglycerides (mg/dl) | 107.1 ± 34.8 | 119.5 ± 27.9 | 0.245 |
Uric acid (mg/dl) | 5.8 ± 1.1 | 5.4 ± 0.8 | 0.175 |
Serum creatinine (mg/dl) | 0.94 ± 0.14 | 0.99 ± 0.20 | 0.402 |
Glycaemia (mg/dl) | 95.7 ± 11.2 | 93.1 ± 7.5 | 0.407 |
MoCA test ES | 1.94 ± 0.94 | 1.89 ± 1.08 | 0.870 |
Word Match Testing ES | 2.00 ± 0.97 | 2.50 ± 1.20 | 0.178 |
Stroop test E ES | 2.22 ± 0.88 | 1.67 ± 1.65 | 0.215 |
Stroop test T ES | 2.67 ± 0.91 | 2.28 ± 1.67 | 0.392 |
EQ-VAS | 65.3 ± 12.8 | 68.1 ± 12.8 | 0.520 |
Augmentation Index (%) | 14.19 ± 10.00 | 18.59 ± 18.21 | 0.400 |
Antihypertensive therapy | Â | Â | Â |
 ACE-inhibitors | 2 (11.1) | 2 (11.1) | 1.000 |
 ATII receptor blockers | 13 (72.2) | 14 (77.8) | 0.700 |
 Beta-blockers | 4 (22.2) | 5 (27.8) | 0.700 |
 Calcium channel antagonists | 7 (38.9) | 6 (33.6) | 0.729 |
 Diuretics | 9 (50.0) | 9 (50.0) | 1.000 |